Advancing Quality Healthcare Metrics Through the Personalization of Treatment for the Patient with Chronic Lymphocytic Leukemia
Once you're logged in, please select the "REGISTER" tab to process your payment and complete your registration.
This case-based activity will cover the diagnosis, treatment, and management of patients with chronic lymphocytic leukemia (CLL).
- Review disease-risk stratification and the use of a prognostic nomogram for estimating time to treatment.
- Examine the first-line management of patients with CLL to maximize adherence while minimizing associated adverse events.
- Discuss the current treatment options for patients with relapsed/refractory CLL and associated limitations.
- Explain the late-stage, clinical trial data for emerging therapies in relapsed/refractory CLL.
Ryan W. Jacobs, MD
Department of Hematology, Levine Cancer Institute, Carolinas Health Care System, Charlotte, NC
Clinical Assistant Professor of Medicine, UNC-Chapel Hill School of Medicine, Chapel Hill, NC
- Hematology - Medical Oncology
- Internal Medicine
- Medical School - Baylor College of Medicine
- Residency - Vanderbilt University Medical Center
- Fellowship - MD Anderson Cancer Center
- Internship - Vanderbilt University Medical Center
- American Board of Internal Medicine - Hematology
- American Board of Internal Medicine - Medical Oncology
During the course of this lecture, Dr. Jacobs may mention the use of medications for both FDA-approved and non-approved indications. Dr. Jacobs has no relevant financial relationships to disclose.
- Ding W et al. Blood. 2015;126(23): abstract 834.
- Porter DL et al. N Engl J Med. 2011;365:725-733.
- Byrd JC et al. Blood. 2014;123:1302-1308.
- Sharman J et al. Blood. 2015;125:2336-2343.
- Awan FT, Byrd JC. Clin Cancer Res. 2014;20:5869-5874.
- Roberts AW et al. N Engl J Med. 2016;374:311-322.
Copyright: All rights reserved. By viewing this activity, participants agree to abide by copyright and trademark laws, intellectual property rights, and all other applicable laws of the United States of America. No part of the syllabus may be used or reproduced in any manner whatsoever without written permission, except in the case of brief quotations embodied in articles or reviews.
Internet CME Policy: The Office of Continuing Medical Education (CME) at Des Moines University (DMU) is committed to protecting the privacy of its customers. DMU CME maintains its Internet site as an information resource and service for health professionals. DMU CME will keep your personal and credit information confidential when you participate in an Internet based program. Your information will never be given to anyone outside of the DMU CME program. DMU CME collects only the information necessary to provide you with the services that you request.
Continuing Education Credit
- MD: This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Iowa Medical Society (IMS). Des Moines University (DMU) is accredited by the IMS to provide continuing medical education for physicians. DMU designates this enduring materials activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- DO: Des Moines University (DMU) is accredited by the American Osteopathic Association (AOA) to provide osteopathic continuing medical education for physicians. DMU designates this program for a maximum of 0.75 AOA Category 2-B credits and will report CME and specialty credits commensurate with the extent of the physician’s participation in this activity.
- Other: This enduring materials activity is designated for 0.75 AMA PRA Category 1 Credit(s)™.
No commercial interest provided financial support for this continuing education activity.
- 0.75 AOA Category 2B
- 0.75 AMA PRA Category 1 Credits™
- 0.75 CE Contact Hours